The mu-opioid receptor-selective peptide antagonists, antanal-1 and antanal-2, produce anticonvulsant effects in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 40, Issue 1, 2013, Pages 126-131

  Fichna, Jakub ^a   Socała, Katarzyna ^b   Nieoczym, Dorota ^b   Gach, Katarzyna ^a   Perlikowska, Renata ^a   Janecka, Anna ^a   Wlaź, Piotr ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

Antanals; Anticonvulsant activity; MOR selective antagonist; Muscular strength; Seizure threshold

Indexed keywords

ANTANAL 1; ANTANAL 2; BETA FUNALTREXAMINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; PENTETRAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CLONUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRIC SHOCK; FORELIMB; GRIP STRENGTH; INTRAVENOUS PENTYLENETETRAZOLE SEIZURE THRESHOLD; MALE; MAXIMAL ELECTROSHOCK SEIZURE THRESHOLD; MOUSE; MUSCLE STRENGTH; MUSCLE TONE; NONHUMAN; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR SEIZURE THRESHOLD; RECEPTOR BLOCKING; SEIZURE THRESHOLD; SKELETAL MUSCLE;

ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; HAND STRENGTH; MALE; MICE; MUSCLE STRENGTH; NALTREXONE; OLIGOPEPTIDES; PENTYLENETETRAZOLE; RECEPTORS, OPIOID, MU; SEIZURES;

EID: 84867894955     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.07.020     Document Type: Article

References (56)

1. Bartenstein P.A., Prevett M.C., Duncan J.S., Hajek M., Wieser H.G. Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography. Epilepsy Res 1994, 18:119-125.
2. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001, 47:217-227.
3. Barton M.E., Peters S.C., Shannon H.E. Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res 2003, 56:17-26.
4. Cheng J.G., Xie X.K. A study on opioid peptides in CSF of patients with epilepsy. Epilepsy Res 1990, 6:141-145.
5. Cohen G.A., Doze V.A., Madison D.V. Opioid inhibition of GABA release from presynaptic terminals of rat hippocampal interneurons. Neuron 1992, 9:325-335.
6. Coimbra N.C., Castro-Souza C., Segato E.N., Nora J.E., Herrero C.F., Tedeschi-Filho W., et al. Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms. Brain Res 2001, 888:314-320.
7. Coimbra N.C., Freitas R.L., Savoldi M., Castro-Souza C., Segato E.N., Kishi R., et al. Opioid neurotransmission in the post-ictal analgesia: involvement of mu(1)-opioid receptor. Brain Res 2001, 903:216-221.
8. Drake C.T., Milner T.A. Mu opioid receptors are in somatodendritic and axonal compartments of GABAergic neurons in rat hippocampal formation. Brain Res 1999, 849:203-215.
9. Felippotti T.T., do Carmo D.R., Paim L.L., Stradiotto N.R., Bicalho U.O., Parada C.A., et al. Effect of a nanostructured dendrimer-naloxonazine complex on endogenous opioid peptides mu1 receptor-mediated post-ictal antinociception. Nanomedicine 2011, 7:871-880.
10. Fichna J., do-Rego J.C., Chung N.N., Lemieux C., Schiller P.W., Poels J., et al. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2). J Med Chem 2007, 50:512-520.
11. Fichna J., Janecka A., Piestrzeniewicz M., Costentin J., do-Rego J.C. Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. Neuropsychopharmacology 2007, 32:813-821.
12. Fichna J., Gach K., Perlikowska R., Cravezic A., Bonnet J.J., do-Rego J.C., et al. Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract. Regul Pept 2010, 162:109-114.
13. Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res 1983, 287:197-210.
14. Frey H.H., Schicht S. Interaction of mu-opioid antagonistic drugs with antiepileptics. Pharmacol Toxicol 1996, 78:264-268.
15. Giardina W.J., Gasior M. Acute seizure tests in epilepsy research: electroshock- and chemical-induced convulsions in the mouse. Curr Protoc Pharmacol 2009, 45:5.22.1-5.22.37.
16. Haffmans J., Dzoljic M.R. Differential epileptogenic potentials of selective mu and delta opiate receptor agonists. J Neural Transm 1983, 57:1-11.
17. Haffmans J., De K.R., Dzoljic M.R. Metabolic rate in different rat brain areas during seizures induced by a specific delta opiate receptor agonist. Brain Res 1984, 302:111-115.
18. Hagen N., Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manage 1997, 14:51-58.
19. Homayoun H., Khavandgar S., Dehpour A.R. The role of alpha2-adrenoceptors in the modulatory effects of morphine on seizure susceptibility in mice. Epilepsia 2002, 43:797-804.
20. Hong J.S., McGinty J.F., Lee P.H., Xie C.W., Mitchell C.L. Relationship between hippocampal opioid peptides and seizures. Prog Neurobiol 1993, 40:507-528.
21. Janecka A., Fichna J., Janecki T. Opioid receptors and their ligands. Curr Top Med Chem 2004, 4:1-17.
22. Jones L.S., Grooms S.Y., Salvadori S., Lazarus L.H. Dermorphin-induced hyperexcitability in hippocampal CA3 and CA1 in vitro. Eur J Pharmacol 1994, 264:39-48.
23. Khavandgar S., Homayoun H., Dehpour A.R. The role of nitric oxide in the proconvulsant effect of delta-opioid agonist SNC80 in mice. Neurosci Lett 2002, 329:237-239.
24. Kimball A.W., Burnett W.T., Doherty D.G. Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice. Radiat Res 1957, 7:1-12.
25. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
26. Kwan P., Sander J.W. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 2004, 75:1376-1381.
27. Lasoń W., Przewłocka B., Przewłocki R. The effect of gamma-hydroxybutyrate and anticonvulsants on opioid peptide content in the rat brain. Life Sci 1983, 33(Suppl. 1):599-602.
28. Lasoń W., Przewłocka B., Coenen A., Przewłocki R., Van L.G. Effects of mu and delta opioid receptor agonists and antagonists on absence epilepsy in WAG/Rij rats. Neuropharmacology 1994, 33:161-166.
29. Lee P.H., Obie J., Hong J.S. Intrahippocampal injections of a specific mu-receptor ligand PL017 produce generalized convulsions in rats. Brain Res 1988, 441:381-385.
30. Lee P.H., Obie J., Hong J.S. Opioids induce convulsions and wet dog shakes in rats: mediation by hippocampal mu, but not delta or kappa opioid receptors. J Neurosci 1989, 9:692-697.
31. Lipman J.J., Spencer P.S. Rapid intracerebroventricular injection assisted by an automatic syringe. J Pharmacol Methods 1980, 4:327-333.
32. Loacker S., Sayyah M., Wittmann W., Herzog H., Schwarzer C. Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 2007, 130:1017-1028.
33. Maurissen J.P., Marable B.R., Andrus A.K., Stebbins K.E. Factors affecting grip strength testing. Neurotoxicol Teratol 2003, 25:543-553.
34. Mazarati A., Liu H., Wasterlain C. Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus. Neuroscience 1999, 89:167-173.
35. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001, 62:111-123.
36. McNamara J.O. Emerging insights into the genesis of epilepsy. Nature 1999, 399:A15-A22.
37. McQuiston A.R., Saggau P. Mu-opioid receptors facilitate the propagation of excitatory activity in rat hippocampal area CA1 by disinhibition of all anatomical layers. J Neurophysiol 2003, 90:1936-1948.
38. Milner T.A., Drake C.T. Ultrastructural evidence for presynaptic mu opioid receptor modulation of synaptic plasticity in NMDA-receptor-containing dendrites in the dentate gyrus. Brain Res Bull 2001, 54:131-140.
39. Mizuno T., Kimura F. Medial septal injection of naloxone elevates acetylcholine release in the hippocampus and induces behavioral seizures in rats. Brain Res 1996, 713:1-7.
40. Nieoczym D., Luszczki J.J., Czuczwar S.J., Wlaź P. Effect of sildenafil on the anticonvulsant action of classical and second-generation antiepileptic drugs in maximal electroshock-induced seizures in mice. Epilepsia 2010, 51:1552-1559.
41. Ondarza R., Trejo-Martinez D., Corona-Amezcua R., Briones M., Rocha L. Evaluation of opioid peptide and muscarinic receptors in human epileptogenic neocortex: an autoradiography study. Epilepsia 2002, 43(Suppl. 5):230-234.
42. Pezet S., Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets 2004, 8:391-399.
43. Piredda S., Lim C.R., Gale K. Intracerebral site of convulsant action of bicuculline. Life Sci 1985, 36:1295-1298.
44. Ramabadran K., Bansinath M. Endogenous opioid peptides and epilepsy. Int J Clin Pharmacol Ther Toxicol 1990, 28:47-62.
45. Rao T.L., Mummaneni N., El-Etr A.A. Convulsions: an unusual response to intravenous fentanyl administration. Anesth Analg 1982, 61:1020-1021.
46. Ribak C.E., Anderson L. Ultrastructure of the pyramidal basket cells in the dentate gyrus of the rat. J Comp Neurol 1980, 192:903-916.
47. Saboory E., Derchansky M., Ismaili M., Jahromi S.S., Brull R., Carlen P.L., et al. Mechanisms of morphine enhancement of spontaneous seizure activity. Anesth Analg 2007, 105:1729-1735. [table].
48. Schwartzkroin P.A., Kunkel D.D. Morphology of identified interneurons in the CA1 regions of guinea pig hippocampus. J Comp Neurol 1985, 232:205-218.
49. Shafaroodi H., Samini M., Moezi L., Homayoun H., Sadeghipour H., Tavakoli S., et al. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 2004, 47:390-400.
50. Shafaroodi H., Baradaran N., Moezi L., Dehpour S., Kabiri T., Dehpour A.R. Morphine sensitization in the pentylenetetrazole-induced clonic seizure threshold in mice: role of nitric oxide and mu receptors. Epilepsy Behav 2011, 20:602-606.
51. Skyers P.S., Einheber S., Pierce J.P., Milner T.A. Increased mu-opioid receptor labeling is found on inner molecular layer terminals of the dentate gyrus following seizures. Exp Neurol 2003, 179:200-209.
52. Tortella F.C. Endogenous opioid peptides and epilepsy: quieting the seizing brain?. Trends Pharmacol Sci 1988, 9:366-372.
53. Vaughan C.W., Ingram S.L., Connor M.A., Christie M.J. How opioids inhibit GABA-mediated neurotransmission. Nature 1997, 390:611-614.
54. Yajima Y., Narita M., Takahashi-Nakano Y., Misawa M., Nagase H., Mizoguchi H., et al. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Res 2000, 862:120-126.
55. Zhang H.N., Ko M.C. Seizure activity involved in the up-regulation of BDNF mRNA expression by activation of central mu opioid receptors. Neuroscience 2009, 161:301-310.
56. Zieglgansberger W., French E.D., Siggins G.R., Bloom F.E. Opioid peptides may excite hippocampal pyramidal neurons by inhibiting adjacent inhibitory interneurons. Science 1979, 205:415-417.